Last reviewed · How we verify

NCT04912934: COVID-19

The Relationship Between COVID-19 Anxiety Level and Emotional Eating in Individuals With Metabolic Syndrome

Completed Last updated 3 June 2021
What this trial tests

trial testing A survey form was applied to individuals included in the study face-to-face. in Metabolic Syndrome in 214 participants. Completed in 12 December 2020.

Timeline
20 June 2020
Primary endpoint
20 November 2020
12 December 2020

Quick facts

Lead sponsorOrdu University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment214
Start date20 June 2020
Primary completion20 November 2020
Estimated completion12 December 2020
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Ordu University

Who can join

Adults 18 to 70, any sex, with Metabolic Syndrome or Emotional Eating. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim was to determine the coronavirus anxiety levels and emotional eating status of cases with diagnosis of MetS according to diagnostic criteria published by the International Diabetic Federation (IDF) in 2005 and healthy individuals with similar BMI to MetS subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Metabolic Syndrome

Currently open trials in the same condition.

Other Ordu University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04912934.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing